申联生物：股东UBI拟减持不超3%公司股份

Core Viewpoint - UBI, a major shareholder of Shenlian Bio, plans to reduce its stake in the company to fund clinical trials and commercialization of its Alzheimer's peptide vaccine and related manufacturing base in China [1] Shareholder Reduction Plan - UBI intends to reduce its holdings by selling 4,106,440 shares through centralized bidding on the Shanghai Stock Exchange, which represents up to 1.00% of the total shares [1] - Additionally, UBI plans to sell 8,212,880 shares via block trading, accounting for up to 2.00% of the total shares [1] - The share reduction will occur within three months after a 15 trading day period following the announcement and will be at market price, not lower than the initial public offering price [1]